TTrialPathMatch Me to Trials
← Back to trials
RecruitingType 2 Diabetes Mellitus

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of tifeglipron for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Sponsor: Hoffmann-La Roche

You may qualify if…

  • ✓ Have a diagnosis of Type 2 diabetes mellitus (T2D) for at least 6 months before screening
  • ✓ Have an HbA1c ≥7% and ≤10.5% at screening
  • ✓ Management of T2D with diet and exercise alone or with either a stable dose of metformin or/and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
  • ✓ Body mass index (BMI) ≥23.0 kg/m\^2 at screening
  • ✓ A stable body weight within 3 months prior to screening (maximum 5% self-reported body weight gain and/or loss)

You may not qualify if…

  • ✕ Have Type 1 diabetes (T1D), history of ketosis or hyperosmolar state/coma, or any other types of diabetes except T2D
  • ✕ Have had 1 or more episodes of Level 3 hypoglycemia or has hypoglycemia unawareness within the 6 months prior to screening
  • ✕ History or presence of proliferative diabetic retinopathy, diabetic macular edema, or non-proliferative diabetic retinopathy that requires acute treatment
  • ✕ Evidence of clinically significant/active nephropathy or neuropathy (including resting tachycardia, orthostatic hypotension, and diabetic diarrhea)
  • ✕ Current treatment or treatment within 3 months of screening with any other anti-hyperglycemic medication except metformin or SGLT-2 inhibitors
  • ✕ Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome)
  • ✕ Have a known, clinically significant gastric emptying abnormality
  • ✕ Have poorly controlled hypertension at screening, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension

Where it's recruiting

Arizona

Tucson

California

Lake Forest · Rancho Cucamonga · Spring Valley

Connecticut

Waterbury

District of Columbia

Washington D.C.

Florida

Clermont · Pembroke Pines

Georgia

Union City

Illinois

Oak Lawn

Montana

Butte

New York

Cedarhurst

North Carolina

Statesville · Wilmington

Ohio

Lima

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT07112872 · last updated 2026-11-12

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Pla · TrialPath